Natera, Inc. $NTRA Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 1,645.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,704 shares of the medical research company’s stock after acquiring an additional 73,252 shares during the quarter. SG Americas Securities LLC’s holdings in Natera were worth $12,508,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in NTRA. Vanguard Group Inc. boosted its position in shares of Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after buying an additional 282,826 shares during the period. JPMorgan Chase & Co. lifted its stake in Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after purchasing an additional 3,263,822 shares during the last quarter. Geode Capital Management LLC increased its stake in Natera by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock valued at $430,640,000 after purchasing an additional 166,768 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Natera by 20.6% during the second quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock worth $327,346,000 after purchasing an additional 330,696 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of Natera by 44.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock worth $291,717,000 after buying an additional 532,769 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Down 5.8%

Shares of NASDAQ NTRA opened at $239.56 on Friday. The company has a 50-day moving average of $226.34 and a two-hundred day moving average of $185.64. The company has a market cap of $33.14 billion, a PE ratio of -104.61 and a beta of 1.62. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.26) EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Major banks initiate or reaffirm buy ratings on Natera, which can attract more institutional demand and support the stock. Citigroup initiates coverage of Natera (NTRA) with buy recommendation
• Positive Sentiment: Piper Sandler issued a buy on Natera, reinforcing recent bullish analyst activity and signaling continued confidence in the company’s growth trajectory. Natera (NTRA) Receives a Buy from Piper Sandler
• Positive Sentiment: Guggenheim reiterated its buy rating, joining other firms that have raised price targets — a supportive backdrop for sentiment and mid‑term upside. Guggenheim Sticks to Their Buy Rating for Natera (NTRA)
• Positive Sentiment: Natera announced a collaboration with Exelixis on the phase 3 STELLAR‑316 colorectal cancer trial — this expands potential clinical use cases for Natera’s oncology assays and could drive future revenue if tied to companion diagnostics/monitoring. Exelixis and Natera to Collaborate on STELLAR-316
• Neutral Sentiment: Analyst consensus remains skewed positive overall (MarketBeat/AmericanBankingNews show a “Moderate Buy” average rating and a consensus price target in the low‑to mid‑$200s), implying expectations are baked into current levels. Natera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Routine market data/price pages track the share move but add no new catalyst. Natera (NTRA) share price
• Negative Sentiment: Significant insider selling was reported (aggregate reports note roughly US$47M in insider sales recently), which can signal near‑term liquidity or confidence concerns and often pressures the stock. Insiders At Natera Sold US$47m In Stock
• Negative Sentiment: Company insiders including CEO Steven Chapman and other executives (Solomon Moshkevich) recently filed Form 4 sales (small single‑digit percentage reductions in holdings). Multiple, recurring insider sales can amplify investor caution. Solomon Moshkevich Sells 2,951 Shares of Natera (NASDAQ:NTRA) Stock

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NTRA. BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 price objective for the company in a report on Monday, October 27th. Barclays raised their price objective on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. UBS Group increased their price objective on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Canaccord Genuity Group raised their price objective on Natera from $250.00 to $285.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Morgan Stanley upped their target price on shares of Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Sixteen analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $238.89.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 3,848 shares of Natera stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $229.08, for a total value of $881,499.84. Following the transaction, the chief executive officer owned 136,568 shares of the company’s stock, valued at approximately $31,284,997.44. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $236.12, for a total value of $17,709,000.00. Following the transaction, the director directly owned 1,154,198 shares of the company’s stock, valued at $272,529,231.76. This represents a 6.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 343,280 shares of company stock worth $73,566,011 over the last 90 days. 5.63% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.